473 related articles for article (PubMed ID: 26181206)
1. Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF).
Tan BS; Tiong KH; Choo HL; Chung FF; Hii LW; Tan SH; Yap IK; Pani S; Khor NT; Wong SF; Rosli R; Cheong SK; Leong CO
Cell Death Dis; 2015 Jul; 6(7):e1826. PubMed ID: 26181206
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
[TBL] [Abstract][Full Text] [Related]
3. An N
Uddin MB; Roy KR; Hosain SB; Khiste SK; Hill RA; Jois SD; Zhao Y; Tackett AJ; Liu YY
Biochem Pharmacol; 2019 Feb; 160():134-145. PubMed ID: 30578766
[TBL] [Abstract][Full Text] [Related]
4. A common gain of function of p53 cancer mutants in inducing genetic instability.
Liu DP; Song H; Xu Y
Oncogene; 2010 Feb; 29(7):949-56. PubMed ID: 19881536
[TBL] [Abstract][Full Text] [Related]
5. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
6. The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins.
Wei S; Wang H; Lu C; Malmut S; Zhang J; Ren S; Yu G; Wang W; Tang DD; Yan C
J Biol Chem; 2014 Mar; 289(13):8947-59. PubMed ID: 24554706
[TBL] [Abstract][Full Text] [Related]
7. Caveolin-1 inhibits cell detachment-induced p53 activation and anoikis by upregulation of insulin-like growth factor-I receptors and signaling.
Ravid D; Maor S; Werner H; Liscovitch M
Oncogene; 2005 Feb; 24(8):1338-47. PubMed ID: 15592498
[TBL] [Abstract][Full Text] [Related]
8. Src activation regulates anoikis in human colon tumor cell lines.
Windham TC; Parikh NU; Siwak DR; Summy JM; McConkey DJ; Kraker AJ; Gallick GE
Oncogene; 2002 Nov; 21(51):7797-807. PubMed ID: 12420216
[TBL] [Abstract][Full Text] [Related]
9. Hotspot mutant p53-R273H inhibits KLF6 expression to promote cell migration and tumor metastasis.
Sun S; Chen H; Sun L; Wang M; Wu X; Xiao ZJ
Cell Death Dis; 2020 Jul; 11(7):595. PubMed ID: 32733026
[TBL] [Abstract][Full Text] [Related]
10. Functional role and oncogene-regulated expression of the BH3-only factor Bmf in mammary epithelial anoikis and morphogenesis.
Schmelzle T; Mailleux AA; Overholtzer M; Carroll JS; Solimini NL; Lightcap ES; Veiby OP; Brugge JS
Proc Natl Acad Sci U S A; 2007 Mar; 104(10):3787-92. PubMed ID: 17360431
[TBL] [Abstract][Full Text] [Related]
11. WIF1 can effectively co-regulate pro-apoptotic activity through the combination with DKK1.
Ko YB; Kim BR; Yoon K; Choi EK; Seo SH; Lee Y; Lee MA; Yang JB; Park MS; Rho SB
Cell Signal; 2014 Nov; 26(11):2562-72. PubMed ID: 25086206
[TBL] [Abstract][Full Text] [Related]
12. Induction of genetic instability by gain-of-function p53 cancer mutants.
Xu Y
Oncogene; 2008 Jun; 27(25):3501-7. PubMed ID: 18223686
[TBL] [Abstract][Full Text] [Related]
13. Restraining FOXO3-dependent transcriptional BMF activation underpins tumour growth and metastasis of E-cadherin-negative breast cancer.
Hornsveld M; Tenhagen M; van de Ven RA; Smits AM; van Triest MH; van Amersfoort M; Kloet DE; Dansen TB; Burgering BM; Derksen PW
Cell Death Differ; 2016 Sep; 23(9):1483-92. PubMed ID: 27035620
[TBL] [Abstract][Full Text] [Related]
14. Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high levels of reactive oxygen species.
Kalo E; Kogan-Sakin I; Solomon H; Bar-Nathan E; Shay M; Shetzer Y; Dekel E; Goldfinger N; Buganim Y; Stambolsky P; Goldstein I; Madar S; Rotter V
J Cell Sci; 2012 Nov; 125(Pt 22):5578-86. PubMed ID: 22899716
[TBL] [Abstract][Full Text] [Related]
15. Normal p53 status and function despite the development of drug resistance in human breast cancer cells.
Wosikowski K; Regis JT; Robey RW; Alvarez M; Buters JT; Gudas JM; Bates SE
Cell Growth Differ; 1995 Nov; 6(11):1395-403. PubMed ID: 8562478
[TBL] [Abstract][Full Text] [Related]
16. Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway.
Dong P; Xu Z; Jia N; Li D; Feng Y
Mol Cancer; 2009 Nov; 8():103. PubMed ID: 19917135
[TBL] [Abstract][Full Text] [Related]
17. Mutant p53 mediates survival of breast cancer cells.
Lim LY; Vidnovic N; Ellisen LW; Leong CO
Br J Cancer; 2009 Nov; 101(9):1606-12. PubMed ID: 19773755
[TBL] [Abstract][Full Text] [Related]
18. Mutant TP53 G245C and R273H promote cellular malignancy in esophageal squamous cell carcinoma.
Kang N; Wang Y; Guo S; Ou Y; Wang G; Chen J; Li D; Zhan Q
BMC Cell Biol; 2018 Aug; 19(1):16. PubMed ID: 30126368
[TBL] [Abstract][Full Text] [Related]
19. p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3.
Wong RP; Tsang WP; Chau PY; Co NN; Tsang TY; Kwok TT
Mol Cancer Ther; 2007 Mar; 6(3):1054-61. PubMed ID: 17363498
[TBL] [Abstract][Full Text] [Related]
20. Involvement of Bcl-2 family members, phosphatidylinositol 3'-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer.
Shankar S; Srivastava RK
Int J Oncol; 2007 Apr; 30(4):905-18. PubMed ID: 17332930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
